Viewing nowCombinationSitapomin Alpha Tablet 50/500 mg
Sitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Daehan New Pharm Co., Ltd.

MFDS item code 202200112 · Approved 2022.01.06 · Insurance code 669908240
Improvement of blood glucose control in type 2 diabetes mellitus
This medication is used in conjunction with diet and exercise to help control blood sugar levels in patients with type 2 diabetes. It can be used when a patient has not previously taken diabetes medications, or when blood sugar control is insufficient with monotherapy. Additionally, it is administered when blood sugar control is difficult with either metformin or sitagliptin monotherapy, or when replacing a combination therapy of these two medications. In cases where blood sugar control is not adequate, it can be used in combination with sulfonylureas, thiazolidinediones, or insulin to improve blood sugar management. This medication is employed in these various scenarios to facilitate more effective blood sugar control.
The dose of this product for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This product is generally taken 2 times daily with food. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. The initial dose of this product should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no previous history of antidiabetic drug treatment who do not achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose of this product is 1 tablet of 50/500 mg 2 times daily. The dose may be increased to 1 tablet of 50/1000 mg 2 times daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this product (see Precautions for Use, 2. Do not administer to the following patients). 2. Patients receiving metformin: - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this product is sitagliptin 50 mg 2 times daily (total daily dose of 100 mg) and the patient's existing metformin dose. - Patients switching from concomitant sitagliptin and metformin therapy to this product may start at their existing doses of sitagliptin and metformin. 3. Patients who cannot achieve adequate glycemic control with concomitant metformin and sulfonylurea therapy, metformin and insulin therapy, or metformin and thiazolidinedione therapy: The initial dose of this product is sitagliptin 50 mg 2 times daily (total daily dose of 100 mg). The initial dose of metformin should be determined based on the patient's blood glucose level and existing dose. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. When this product is administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching to this product in patients previously treated with other oral antihyperglycemic agents. Any change in treatment for type 2 diabetes may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This product may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who have no other symptoms that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this product, since the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg 2 times daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this product should be discontinued immediately. Patients with hepatic impairment This product should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).
This medication can cause serious allergic reactions, although rare; therefore, if symptoms such as skin rash, shortness of breath, or swelling of the face or neck occur after administration, immediate discontinuation and consultation with a physician is advised. This medication can induce severe inflammation of the pancreas, known as pancreatitis; hence, if symptoms like abdominal pain, vomiting, or fever arise, medical personnel should be notified immediately. Patients with severely impaired renal function, acute heart failure, or severe infections should not use this medication, and it should particularly be discontinued before and after examinations involving contrast agents. It is safer not to use this medication in pregnant women or those who may become pregnant, as well as nursing mothers. Patients should be cautious of hypoglycemic symptoms while taking this medication, especially if it is used in combination with other antidiabetic agents as the risk of hypoglycemia may increase. The metformin component can rarely cause lactic acidosis, a life-threatening condition; hence, heightened caution is advised in cases of dehydration, severe infections, or heart disease. Patients should have regular kidney function and blood tests during the course of this medication, and it is advisable to monitor vitamin B12 levels as well. Alcohol consumption can increase the risk of side effects from this medication, so it is important to avoid excessive drinking while on this medication. In case of surgery or significant trauma, the medication should be temporarily discontinued, and it should be resumed only after the patient's condition stabilizes. When administering this medication to elderly patients, dosage adjustments must be made in consideration of renal function, and regular monitoring should be implemented to ensure safe management.
Anaphylaxis, angioedema, Stevens-Johnson syndrome, hemorrhagic pancreatitis, necrotizing pancreatitis, acute pancreatitis, lactic acidosis, hypoglycemia, diarrhea, upper respiratory infection, headache, nausea, vomiting, abdominal pain, nasopharyngitis, constipation, arthralgia with severe and disabling symptoms, vesicular pemphigoid, myalgia, limb pain, back pain, interstitial lung disease, pruritus, thrombocytopenia, dermatitis, loss of appetite, weight loss, dyspnea, unstable angina, dizziness, acute renal failure, decreased appetite, gastrointestinal disorder, itching
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent exposure to air and moisture, and it is recommended to keep it at room temperature between 1 and 30 degrees Celsius. Proper storage will help maintain the medication's effectiveness and prevent degradation.
Light pink oval film-coated tablet
30 tablets/box [10 tablets/PTP × 3]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Daehan New Pharm Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Eden Pharma Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.